How immune responses affect triple-negative breast cancer spreading to the brain
Do Tumor-Immune Interactions Prime Systemic Tolerance of Triple-Negative Breast Cancer Brain Metastases?
This work looks at how interactions between tumors and the immune system may let triple-negative breast cancer spread to the brain, with attention to differences seen in women of African ancestry.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10746898 on NIH RePORTER |
What this research studies
From my point of view, researchers will map the immune cells and molecular signals around triple-negative breast tumors that reach the brain to see what lets them grow there. They will compare those brain metastases to primary breast tumors and use laboratory models and patient-derived samples to track key pathways. The team will apply systems-biology analyses to identify patterns linked to higher risk and to racial differences in TNBC. Findings will guide ideas for therapies or ways to stop brain spread in the future.
Who could benefit from this research
Good fit: People with triple-negative breast cancer—especially those who have or are at high risk for brain metastases and who are willing to provide tumor or blood samples—would be the best match.
Not a fit: People with other breast cancer subtypes or unrelated diseases, or those who cannot provide samples or attend study visits, are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this could point to new immune-based strategies or targets to prevent or treat brain metastases from triple-negative breast cancer and help address racial disparities.
How similar studies have performed: Previous work shows immune cells matter for outcomes in primary TNBC, but applying a systems-biology approach specifically to TNBC brain metastases and ancestry-linked differences is relatively new.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Umeh Garcia, Maxine — University of California at Davis
- Study coordinator: Umeh Garcia, Maxine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.